Axon Enterprise, Inc. (NASDAQ:AXON) Director Caitlin Elizabeth Kalinowski Sells 1,300 Shares of Stock

Axon Enterprise, Inc. (NASDAQ:AXON) Director Caitlin Elizabeth Kalinowski sold 1,300 shares of the stock in a transaction on Monday, May 19th. The shares were sold at an average price of $738.84, for a total value of $960,492.00. Following the sale, the director now owns 4,829 shares in the company, valued at $3,567,858.36. The trade was a 21.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Axon Enterprise Stock Performance

AXON stock opened at $742.75 on Wednesday. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. The business’s fifty day simple moving average is $592.46 and its two-hundred day simple moving average is $598.92. Axon Enterprise, Inc. has a twelve month low of $273.52 and a twelve month high of $744.51. The firm has a market cap of $57.82 billion, a price-to-earnings ratio of 191.93, a PEG ratio of 5.17 and a beta of 1.24.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The business had revenue of $603.63 million for the quarter, compared to the consensus estimate of $585.67 million. During the same quarter in the prior year, the company earned $1.15 EPS. The business’s revenue was up 31.3% compared to the same quarter last year. Analysts predict that Axon Enterprise, Inc. will post 5.8 earnings per share for the current year.

Hedge Funds Weigh In On Axon Enterprise

A number of hedge funds and other institutional investors have recently made changes to their positions in AXON. Ritholtz Wealth Management grew its position in shares of Axon Enterprise by 22.7% during the 4th quarter. Ritholtz Wealth Management now owns 616 shares of the biotechnology company’s stock worth $366,000 after buying an additional 114 shares in the last quarter. Merit Financial Group LLC grew its position in shares of Axon Enterprise by 19.0% during the 4th quarter. Merit Financial Group LLC now owns 5,579 shares of the biotechnology company’s stock worth $3,316,000 after buying an additional 889 shares in the last quarter. Premier Path Wealth Partners LLC bought a new position in shares of Axon Enterprise during the 4th quarter worth $222,000. HB Wealth Management LLC grew its position in shares of Axon Enterprise by 5.0% during the 4th quarter. HB Wealth Management LLC now owns 1,441 shares of the biotechnology company’s stock worth $856,000 after buying an additional 68 shares in the last quarter. Finally, Smith Salley Wealth Management bought a new stake in Axon Enterprise during the fourth quarter valued at about $403,000. Institutional investors own 79.08% of the company’s stock.

Analyst Upgrades and Downgrades

AXON has been the topic of several recent research reports. JMP Securities restated an “outperform” rating on shares of Axon Enterprise in a report on Tuesday, February 4th. Northcoast Research lowered Axon Enterprise from a “buy” rating to a “neutral” rating in a report on Wednesday, February 19th. Craig Hallum lowered Axon Enterprise from a “buy” rating to a “cautious” rating in a report on Monday, March 10th. Needham & Company LLC increased their target price on Axon Enterprise from $600.00 to $750.00 and gave the stock a “buy” rating in a research note on Thursday, May 8th. Finally, The Goldman Sachs Group increased their target price on Axon Enterprise from $730.00 to $830.00 and gave the stock a “buy” rating in a research note on Wednesday, May 14th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $652.73.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.